The QualityStocks Daily Thursday, June 18th, 2020

Today's Top 3 Investment Newsletters

StockMarketWatch (ALPN) +134.98%

QualityStocks (VBIO) +99.80%

MarketClub Analysis (UONE) +96.70%

The QualityStocks Daily Stock List

Bonanza Goldfields Corp. (BONZ)

Penny Stock Dream, Small Cap Network, All Penny Stocks, Mining Capital, OTC.Watch, YCharts, Market Exclusive, Dividend.com, Nasdaq, Mining.com, Hot Penny Stocks, Proactive Investors, Pink Investing, Accesswire, OTC Markets, TipRanks, Stockwatch, PR Newswire, Morningstar, TMXmoney, TradingView, Dividend Investor, Seeking Alpha, InvestorsHub, Stockhouse, Simply Wall St, Central Charts, and Investors Hangout reported beforehand on Bonanza Goldfields Corp. (BONZ), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bonanza Goldfields Corp. operates as a mining and mineral exploration company. It has numerous past producing mines in the States of Nevada and Arizona. Its flagship property is the Montezuma Stonewall group of patented mining claims (60 acres) situated 10 miles south of Goldfield, Nevada. Founded in 2008, Bonanza Goldfields is based in Las Vegas, Nevada and lists on the OTC Markets.

Goldfield is famous for its bonanza gold ores. From 1907 to 1951 the Goldfield Mining District produced 4,160,000 ounces of gold and 1,440,000 ounces of silver. Bonanza Goldfields has a dominant land position in the Wallapai Mining District, located in and about Chloride, Arizona. The Company has 492 acres of patented mining claims comprising eight mines that produced gold, silver, lead, and zinc. They are the Hercules, Badger, Rambler, Payroll, Towne, Summit, Golden Gem, and Daisy Twin Mines.

Bonanza Goldfields’ Tom Reed Jr. Mine is in the Oatman Mining District in Arizona. From 1906 to 1942, the Oatman Mining District produced two million ounces of gold and 1.5 million ounces of silver. The Tom Reed Jr. Mine is located on the next vein south of the Tom Reed Mine, which was and is one of the three major mines at Oatman. The Tom Reed Jr. Mine was last worked in the 1980's.

Bonanza Goldfields also has its Fountain Head Mine. The property historically has produced gold, silver, as well as base metals. Fountain Head is in Stockton Hill, 15 miles north of Kingman, Arizona. The mine is downhill from the Company’s Summit Mine. In the past, ore from the Summit and Fountain Head Mines was trucked to Bonanza’s Golden Gem Millsite for treatment. Fountain Head is Bonanza Goldfields’ eighth mine positioned within a short haul from the Golden Gem Millsite. The Golden Gem, Idaho, Broken Hills, Columbus, O'Brien, Daisy Twins, and Summit Mines are also close by.

Bonanza Goldfields announced in January 2020 that it increased the size of its Cupid Gold Project to 1,064 acres from 217 acres. The Cupid Gold property is in Esmeralda County, Nevada, 15 miles south of Goldfield. The Cupid Gold Project now covers substantially all of the area of outcropping alteration/mineralization earlier included in the Kinross CPD property. The gold deposits at Goldfield are associated with alunite, which is also plentiful along the eastern portion of the Cupid Gold property.

Ms. Barbara McIntyre Bauman is President/Chief Executive Officer/Director of Bonanza Goldfields. Ms. McIntyre Bauman is an experienced mining executive. She has greater than 15 years’ experience in the mining and mineral exploration business, and more than 10 years in telecommunications and information technology (IT).

Bonanza Goldfields Corp. (BONZ), closed Thursday's trading session at $0.0015, off by 11.7647%, on 5,265 volume with 1 trade. The average volume for the last 3 months is 1,033,550 and the stock's 52-week low/high is $0.000799999/$0.0062.

chart

Electrameccanica Vehicles Corp. (SOLO)

Zacks, Market Screener, Stockhouse, Finviz, Simply Wall St, last10k, MacroTrends, GuruFocus, Seeking Alpha, Nasdaq, Stockopedia, GlobeNewswire, and Proactive Investors reported beforehand on Electrameccanica Vehicles Corp. (SOLO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Electrameccanica Vehicles Corp. is a designer and manufacturer of environmentally efficient electric vehicles (EVs). Its flagship vehicle is the unique, purpose-built, single-seat EV called the SOLO. Moreover, InterMeccanica is a subsidiary of ElectraMeccanica. This subsidiary has successfully been building high-end specialty cars for 61 years. Electrameccanica Vehicles’ shares trade on the NasdaqGS. Incorporated in 2015, Electrameccanica Vehicles has its corporate headquarters in Vancouver, British Columbia.

SOLO features include Zero to 60 in 10 seconds. It has a top speed of 80 MPH. SOLO speeds up one’s commute while decreasing one’s environmental footprint. The charge time is 2.5 hours - 220V (15 percent - 90 percent); 110V (level 1): 8 hours for approximately 60 percent.

SOLO is powered by a 17.3 kWh NCA Battery, liquid cooled, with up to a 100 mile range. The battery is compatible with universal charging stations everywhere. Solo has 99 percent fewer parts than a combustion engine. In addition, SOLO features a heated seat and a Bluetooth stereo.

Last week, ElectraMeccanica Vehicles provided an update regarding its continuing search for a U.S. based assembly facility and engineering technical center. It has narrowed its list to the following five States (in no particular order): Arizona, Colorado, Florida, North Carolina, and Tennessee. The expectation is that the proposed new U.S. facility will employ up to 250 people and feature a state-of-the art engineering technical center, including plans for multiple labs to support ongoing vehicle, chassis, and power electronics testing and also comprehensive research facilities.

This week, ElectraMeccanica Vehicles announced the accelerated expansion of its retail footprint for its flagship SOLO EV with new locations planned for the States of Arizona and Oregon. In recent weeks, individual States and Counties have started the process of re-opening storefronts and businesses at differing rates and times. In recognition of this developing situation, ElectraMeccanica Vehicles has responded with an updated retail awareness strategy centered on entering select, new markets where interest and consumer demand is greatest.

Furthermore, Electrameccanica Vehicles presently maintains a SOLO EV storefront at Westfield Century City in Los Angeles, California, with a second location under contract at Westfield Fashion Square, a premier shopping center in Sherman Oaks, California.

Electrameccanica Vehicles Corp. (SOLO), closed Thursday's trading session at $1.85, off by 6.5657%, on 4,327,922 volume with 13,470 trades. The average volume for the last 3 months is 3,412,523 and the stock's 52-week low/high is $0.890100002/$3.25.

chart
n

Ensign Energy Services, Inc. (ESVIF)

Street Insider, Capital Cube, MarketBeat, GuruFocus, Stock Target Advisor, All Stocks Today, Morningstar, Barchart, Market Screener, Stockhouse, Wallet Investor, Dividend Investor, Wallmine, Dividend Channel, Stockwatch, Macroaxis, InvestorsHub, and TradingView reported earlier on Ensign Energy Services, Inc. (ESVIF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Ensign Energy Services, Inc., together with its subsidiaries, provides oilfield services to the oil and natural gas industry in the United States, Canada, and worldwide. The Company is an international leader in drilling and servicing wells. It owns and operates a fleet of land drilling rigs, specialty rigs, well servicing rigs, and drilling rigs via Trinidad Drilling International. Established in 1987, Ensign Energy Services is headquartered in Calgary, Alberta.

The Company’s services include drilling, directional drilling, as well as well servicing. Its crews work in the world’s most extreme environments, from arctic to equatorial, desert to rainforest. Pertaining to drilling, Ensign Energy Services offers its clients an extensive fleet of technologically advanced, purpose-built rigs and a complete range of drilling services.

Regarding directional drilling, Ensign Energy Services is an industry leader in the drilling of deep, complex, challenging wells. Its horizontal and directional drilling teams are among the world’s most skilled and experienced. In addition, they are fully equipped with state-of-the-art technology.

Concerning servicing, the Company’s service rigs are purpose-built for industry. The design of them are to move safely, quickly, and also efficiently. Its fleet has hundreds of rigs deployed around the world. Moreover, Ensign’s highly trained, experienced crews are backed by a complete lineup of service rigs to handle the most challenging environments. As of December 31, 2019, Ensign Energy Services operated a fleet of 226 land drilling rigs, 21 specialty coring rigs, and 99 well servicing rigs.

Last month, Ensign Energy Services reported 2020 Q1 results. Revenue for Q1 of 2020 was $383.9 million. This represents a 14 percent decrease from Q1 2019 Revenue of $445.3 million. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) totaled $90.1 million ( $0.55 per common share) in Q1 of 2020, lower by $26.3 million than Adjusted EBITDA of $115.5 million ( $0.74 per common share) in Q1 of 2019.

Net Loss Attributed to Common Shareholders for the three months ended March 31, 2020 was $29.3 million ( $0.18 per common share). This is in comparison to a Net Loss Attributed to Common Shareholders of $22.2 million ( $0.14 per common share) for the three months ended March 31, 2019. Because of the current business environment, Ensign Energy Services has suspended its quarterly dividend.

Ensign Energy Services, Inc. (ESVIF), closed Thursday's trading session at $0.9301, off by 2.0947%, on 7,187 volume with 11 trades. The average volume for the last 3 months is 70,864 and the stock's 52-week low/high is $0.163200005/$3.77500009.

chart

FSD Pharma, Inc. (HUGE)

Zacks, MacroTrends, Finbox, Stockopedia, Stockwatch, Barchart, InvestorsHub, Newsfilecorp, Financial Buzz, Investing.com, Small Cap Power, CannabisMarketCap, Midas Letter, 5iResearch, Proactive Investors, Nasdaq, Market Screener, Stockchase, Investing News, Seeking Alpha, Stockhouse, and Simply Wall St reported earlier on FSD Pharma, Inc. (HUGE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma, Inc. is a publicly traded holding company since May of 2018. FSD BioSciences, Inc. is a wholly-owned subsidiary. FSD BioSciences is a specialty biotech pharmaceutical R&D company. Its emphasis is on developing over time a strong pipeline of FDA (Food and Drug Administration)-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. FSD Pharma lists on the NasdaqGS.

FSD also has its wholly-owned subsidiary called FV Pharma. This subsidiary is a licensed producer under Canada's Cannabis Act and Regulations. It received its cultivation license on October 13, 2017, and its full Sale for Medical Purposes license on June 21, 2019. FV Pharma is licensed to cultivate cannabis in roughly 25,000 square feet of its facility in Cobourg, Ontario.

By way of FSD Pharma’s acquisition of Prismic Pharmaceuticals in Q2 of 2019, the Company is also making an effort to help address the opioid crisis through developing opioid-sparing prescription drugs using the ultramicronized formulation of palmitoylethanolamide (PEA). FSD Pharma has a Phase 1 first-in-human safety and tolerability trial for its lead candidate, FSD-201, now taking place in Australia.

Earlier this month, FSD Pharma announced that the FDA gave the Company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19. Severe COVID-19 is characterized by an over-exuberant inflammatory response. This may lead to a cytokine storm and ultimately death. FSD Pharma is centered on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

Based on the FDA feedback received to date, FSD Pharma expects the trial will be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care (SOC) versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19.

FSD Pharma, Inc. (HUGE), closed Thursday's trading session at $4.26, off by 0.930233%, on 73,239 volume with 523 trades. The average volume for the last 3 months is 319,073 and the stock's 52-week low/high is $2.3901/$32.0675392.

chart

Humanigen, Inc. (HGEN)

NetworkNewsWire, Whale Wisdom, TipRanks, Proactive Investors, Stockopedia, GlobeNewswire, Proactive Investors, 4-Traders, Trading View, PharmaShots, Stockhouse, StreetWise Reports, Street Insider, Wall Street Analyzer, Barchart, Investors Hangout, StockInvest.us, OTC Dynamics, InvestorsHub, Dividend Investor, Insider Financial, Morningstar, BioWorld, and Equity Clock reported earlier on Humanigen, Inc. (HGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. is developing its Humaneered® proprietary monoclonal antibodies to address critical unmet needs in today's most advanced cancer therapies. A biopharmaceutical Company, it is developing its portfolio of Humaneered® monoclonal antibodies focused on CAR-T optimization and immuno-oncology. Humaneering is a patented proprietary technology for converting suboptimal antibodies into human antibodies suitable for chronic therapies, in part, because of low immunogenicity. The Company formerly went by the name KaloBios Pharmaceuticals, Inc. It changed its corporate name to Humanigen, Inc. in August of 2017. OTCQB-listed, Humanigen is based in Burlingame, California.

Originated from the Company’s Humaneered® platform, lenzilumab and ifabotuzumab, and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab targets GM-CSF. It is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for hematologic cancers.

Ifabotuzumab targets the Eph type-A receptor 3 (EphA3). It is being explored as a potential treatment for glioblastoma multiforme (GBM) and a range of solid tumors, as an optimized naked antibody and as part of an antibody-drug conjugate. It is also being explored as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

HGEN005 selectively targets the eosinophil receptor EMR1. It is being explored as a potential treatment for a range of eosinophilic diseases. This includes eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct.

Humanigen recently announced that the FDA (Food and Drug Administration) approved the administration of lenzilumab for COVID-19 patients under individual patient emergency IND applications to patients under the Company’s compassionate use program. Humanigen is advancing plans to conduct a multicenter, Phase III, randomized, double-blinded, controlled, clinical trial with lenzilumab for the prevention of ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 (SARS-CoV-2) infection in COVID-19 patients.

This week, Humanigen announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ‘First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia’ was published online at medRxiv.org. Patients showed fast clinical improvement with a median time to recovery of five days, median time to discharge of five days, and 100 percent survival to the data cut-off date. Furthermore, patients demonstrated quick improvement in oxygenation, temperature, inflammatory cytokines, and key hematological parameters consistent with improved clinical outcomes.

Moreover, this week, Humanigen subsequently announced additional analysis on the first clinical use of lenzilumab in 12 COVID-19 patients. The ability of lenzilumab to prevent and/or treat cytokine storm has been earlier published. Humanigen believes a combination of lenzilumab to treat cytokine storm and a direct-acting antiviral may be synergistic in the treatment of patients with COVID-19, given the differing mechanisms of action of these two drug categories.

Humanigen, Inc. (HGEN), closed Thursday's trading session at $4.17, up 0.481928%, on 552,285 volume with 486 trades. The average volume for the last 3 months is 258,300 and the stock's 52-week low/high is $0.300000011/$6.30000019.

chart

North Bud Farms, Inc. (NOBDF)

BioSpace, InvestorX, BioPortfolio, Stock Day Media, CannabisMarketCap, TipRanks, Simply Wall St, Investors Hangout, Investor Ideas, WeedStreet420, Cannabis Prospect Magazine, InvestorsHub, mjinvest, Investors Observer, TradingView, GuruFocus, Nasdaq, Morningstar, OTC Markets, Midas Letter, Proactive Investors, Highwater Financial, Wallet Investor, Market Screener, OTC.Watch, Seeking Alpha, GlobeNewswire, Stockhouse, Stockwatch, and Dividend Investor reported previously on North Bud Farms, Inc. (NOBDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

North Bud Farms, Inc., through its wholly-owned subsidiary, GrowPros MMP, Inc., is pursuing a license under The Cannabis Act. It has built a state-of-the-art purpose-built cannabis production facility on 135 acres of agricultural land in Low, Quebec. North Bud, by way of its wholly-owned U.S. subsidiary, Bonfire Brands USA, has acquired cannabis production facilities in the States of Nevada and California. Incorporated in 2016, North Bud Farms is based in Toronto, Ontario. The Company lists on the OTCQB.

The Reno, Nevada property is on 3.2 acres of land that was acquired through the acquisition of Nevada Botanical Science, Inc. a premier cannabis production, research and development (R&D) facility with 5,000 sq. ft. of indoor cultivation that holds medical and adult use licenses for cultivation, extraction, and distribution. The Salinas, California property is located on 11 acres that currently consists of 300,000 sq. ft. of licensable greenhouse space with 60,000 sq. ft. actively cultivating cannabis and a 2,000 sq. ft. building licensed for distribution.

Concerning the Low, Quebec cannabis production facility, upon being fully licensed, North Bud Farms’ facility will produce craft cannabis indoors and farm acres of extraction-grade cannabis outdoors. Further to cultivating outdoors, its Quebec facility is powered by a sustainable and cost-efficient energy source.

North Bud Farms’ wholly-owned subsidiary, GrowPros MMP, Inc., has received its standard cultivation licence from Health Canada for 24,500 sq. ft. of indoor cannabis cultivation space at its purpose-built cannabis production facility situated on 135 acres of agricultural land in Low, Quebec (Quebec Facility). The receipt of this licence allows North Bud to proceed with Phase one (indoor cultivation) at its Quebec Facility.

In May, North Bud Farms announced that regarding its earlier disclosed intention to apply for an amendment to its existing cultivation licence at its Quebec Facility to allow for outdoor cultivation, the Company announced that it submitted to Health Canada all required materials and documentation for the licence amendment. It now awaits the issuance of a licence to allow for a proposed 1 million square feet of outdoor production.

Moreover, North Bud Farms announced it signed a non-binding Letter Of Intent (LOI) to sell all the shares of its U.S. subsidiary, Bonfire Brands USA, Inc. (BBUSA), to an entity controlled by Mr. Justin Braune, the President of BBUSA.

North Bud Farms, Inc. (NOBDF), closed Thursday's trading session at $0.03, even for the day, on 1,000 volume. The average volume for the last 3 months is 4,860 and the stock's 52-week low/high is $0.029899999/$0.237000003.

chart

TearLab Corporation (TEAR)

Zacks, Morningstar, BioSpace, TMXmoney, MacroTrends, Wallet Investor, TipRanks, Simply Wall St, MarketBeat, Proactive Investors, Nasdaq, P&T Community, Market Screener, GlobeNewswire, StockInvest.us, Investing.com, GuruFocus, and Simply Wall St reported earlier on TearLab Corporation (TEAR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A leader in Ocular Surface Diagnostics, TearLab Corporation develops and markets lab-on-a-chip technologies. These technologies enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The Company’s mission is to pioneer the future of tear film diagnostics to elevate patient care. TearLab is headquartered in Escondido, California. The Company lists on the OTC Markets’ OTCQB.

The TearLab Osmolarity Test is for diagnosing Dry Eye Disease. It is the first assay developed for the award-winning TearLab Osmolarity System. The TearLab Osmolarity System is a proprietary in vitro diagnostic tear testing platform. It measures tear film osmolarity for the diagnosis of dry eye disease. Furthermore, it enables eye care practitioners to test for sensitive and specific biomarkers utilizing nanoliters of tear film at the point-of-care.

The TearLab Osmolarity System comprises TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, and also provides a quantitative reading for the operator. TearLab is for professional in vitro diagnostic use only.

Last month, TearLab announced it entered into a definitive agreement wherein Accelmed Partners II (AP-II) will acquire TearLab. In connection with the acquisition, AP-II has agreed to an investment of $25 million over two tranches that will take place in conjunction with the company delisting from the "over the counter" OTCQB market.

TearLab and its senior secured lender, CR Group, have agreed to restructure the terms of the company's outstanding senior secured indebtedness. Post transaction, TearLab will be a private company and AP-II will be the controlling shareholder. Proceeds from the AP-II investment will be used to pay down a portion of TearLab's existing debt, and fund organic and inorganic growth opportunities.

Accelmed Partners (New York, New York) is a foremost U.S. based private equity firm. It focuses on investments in commercial stage HealthTech companies.

TearLab Corporation (TEAR), closed Thursday's trading session at $0.057, up 4.2048%, on 121,865 volume with 11 trades. The average volume for the last 3 months is 152,404 and the stock's 52-week low/high is $0.020099999/$0.215000003.

chart

Allied Esports Entertainment, Inc. (AESE)

Market Chameleon, Venture Beat, TipRanks, Investors Observer, last10k, Street Insider, Morningstar, Stockopedia, ShareInvestor.com, Nasdaq, ETF.com, Business Wire, GuruFocus, Simply Wall St, Seeking Alpha, TradingView, InvestorsHub, ETF Channel, Barchart, and YCharts reported beforehand on Allied Esports Entertainment, Inc. (AESE), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Allied Esports Entertainment, Inc. is a worldwide esports entertainment company listed on the NasdaqGS. It provides unique infrastructure, transformative live experiences, multiplatform content and interactive services to audiences globally via its strategic fusion of two strong entertainment brands: Allied Esports International, Inc. (Allied Esports) and the World Poker Tour (WPT). Incorporated in 2017, Allied Esports Entertainment is based in Irvine, California.

Allied Esports is an award-winning esports enterprise consisting of an international network of dedicated esports properties and content production facilities. Its mission is to connect players, streamers and fans globally through integrated arenas, including its flagship venue, HyperX Esports Arena Las Vegas, its fleet of mobile esports trucks, the HyperX Esports Trucks, and affiliate members of the Allied Esports Property Network that serve as competition battlegrounds and everyday content generation hubs.

World Poker Tour is the premier name in globally televised gaming and entertainment. It has brand presence in land-based tournaments, television, online, as well as mobile. In 2002, WPT sparked the worldwide poker boom with the creation of its iconic television show, now in its 18th season, based on a series of high-stakes poker tournaments. ClubWPT.com is an innovative online membership platform that offers inside access to the WPT.

This month, the WPT® and its partner, partypoker, announced the first WPT Online Series that will take place exclusively on the partypoker platform. The series will take place from May 10-26, 2020. The $3,200 buy-in, $5 million guaranteed WPT Online Championship will highlight the schedule. The WPT Online Championship will occur over the course of the entire festival, with Day 1 flights available starting on May 10.

The entire partypoker series includes $30 million in guarantees and $7 million for the WPT events on the schedule. partypoker.com is one of the oldest, most recognized and trusted online poker brands. Launched in August 2001, partypoker.com is one of the pioneers of the online poker industry.

This week, Allied Esports Entertainment announced its financial results for Q4 and full year ended December 31, 2019, and also an update on a number of important business initiatives. Chief Executive Officer, Mr. Frank Ng, said, "Allied Esports Entertainment wrapped-up a transformational year ending with a strong fourth quarter highlighted by robust topline growth and continued execution of our strategic initiatives. Fourth quarter total revenues of $6.5 million increased 19.5 percent compared to the fourth quarter last year, driven by growth in both our Esports and Poker businesses…we also made significant progress in the fourth quarter with our strategic partnerships announced earlier in the year with Simon Property Group (NYSE: SPG) and TV Azteca and with this momentum, we announced a new relationship with Brookfield Properties…”

Allied Esports Entertainment, Inc. (AESE), closed Thursday's trading session at $2.91, up 39.9038%, on 15,160,130 volume with 58,290 trades. The average volume for the last 3 months is 1,417,140 and the stock's 52-week low/high is $0.400000005/$10.8100004.

chart

urban-gro, Inc. (UGRO)

Street Insider, TipRanks, Stockopedia, last10k, Market Screener, Penny Stock Hub, Proactive Investors, Wallet Investor, Loud News Net, Cannabis Business Executive (CBE), Simply Wall St, Stockhouse, GlobeNewswire, Nasdaq, Dividend.com, Dividend Investor, Barchart, PR Newswire, Morningstar, InvestorsHub and MarketWatch reported previously on urban-gro, Inc. (UGRO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

urban-gro, Inc. is an engineering design services company listed on the OTC Markets’ OTCQX. It integrates complex equipment systems into high-performance indoor cannabis cultivation facilities around the world. The Company bring decades worth of combined commercial cultivation experience to craft fully-integrated systems and technology solutions. urban-gro has its corporate headquarters in Lafayette, Colorado.

With its With Soleil Technologies line of sense and control technology, cultivators are able to monitor their canopy and grow environment conditions from anywhere, 24/7. With its foundational Cultivation Space Planning design services, urban-gro creates cultivation facilities that surpass its customers’ goals for efficient interaction between the people, plants, and processes.

Urban-gro had customized product solutions to meet the needs of commercial cultivators. It provides professionally designed bench plans that maximize cultivation space and provides custom fertigation design unique to a customer’s facility and its needs and challenges. The Company also provides LED, HPS, CMH and Hybrid Lighting Solutions. It also provides Pest Control and Water Treatment.

Integrated Pest Management (IPM) promotes healthy, relatively pest-free crops. Moreover, urban-gro partners with HydroLogic to provide efficient, high-end commercial water filtration systems.

Urban-gro designs custom biological wastewater treatment systems to decrease the levels of salts and BODs before emission to the sewer. The Company’s services include Cultivation Systems Design, MEP Building Engineering, Commissioning and Start-Up, the above-mentioned Integrated Pest Management, Odor Mitigation, and Crop Monitor Technology.

Pertaining to Integrated Design Services, urban-gro is an agricultural solutions enterprise focusing on systems integration and ag-tech for cannabis and high-value food crop markets. The Company is a recognized national leader in the design, equipment procurement, project management, installation oversight, and commissioning of cultivation facility systems. To date, urban-gro has delivered greater than 5,000,000 square feet of facilities across the United States and Canada.

Concerning Commissioning and Facility Start-Up, the Company’s comprehensive commissioning report and checklist provides a client with the confidence that their systems are operating efficiently. In addition, urban-gro’s process includes documentation of their systems and training of staff so they can effectively manage systems.

urban-gro, Inc. (UGRO), closed Thursday's trading session at $1.00, up 96.0784%, on 205 volume with 2 trades. The average volume for the last 3 months is 521 and the stock's 52-week low/high is $0.50999999/$2.5999999.

chart

eMARINE Global, Inc. (EMRN)

TipRanks, Real Investment Advice, StockPulse, TeleTrader, Wallmine, Market Wire News, TradingView, Street Insider, Wallet Investor, Stockhouse, Market Screener, InvestorsHub, Morningstar, Stockopedia, Nasdaq, GlobeNewswire, Global Banking and Finance, Stockwatch, Simply Wall St, and Financial Buzz reported beforehand on eMARINE Global, Inc. (EMRN), and today we report the Company, here at the QualityStocks Daily Newsletter.

eMARINE Global, Inc. is a top provider of information and communications technology (ICT) for the maritime industry. It provides solutions for the collection, integration and display of maritime information abroad and ashore through electronic means to enhance berth to berth navigation and related services. The Company formerly went by the name Pollex, Inc. It changed its name to eMarine Global, Inc. in August of 2017. Incorporated in 2001, eMARINE Global has offices in Ulsan and Seoul, South Korea.

eMARINE Global’s solutions provide the most efficient means to secure the safety of life at sea and to protect the marine environment. All products and services are offered through subscription, installation, updates and/or maintenance contracts.

eMARINE Global is working with a growing base of marquee customers to reach maritime ICT convergence by way of fully integrated products and services. The Company offers state-of-the-art e-navigation, marine Internet of Things (IoT), and marine big data solutions, primarily in Korea with near-term expansion into U.S. and Chinese markets.

eMARINE Global offers electronic chart display and information systems (ECDIS), a computer-based navigation system; and electronic navigation charts (ENC), which integrates position information from the global positioning system (GPS) and other navigational sensors, including radar, fathometer, and automatic identification systems. eMARINE Global also provides smart ship solutions, including intra-ship integrated gateway (ISIG), an intra-ship network; collision avoidance and optimal voyage systems; and remote maintenance and engine monitoring systems.

The Company engages in the distribution of overseas solutions, such as CARIS, a maritime GIS software; digital charts; and Hatteland, a maritime-specialized hardware. Moreover, it provides Aids to Navigation (AtoN) management systems consisting of maritime weather signals total management system, and e-A2N device.

Yesterday, eMARINE Global announced it was chosen as the preferred bidder for a large-scale vessel traffic system (VTS) project for the Korean Coast Guard. The Company will work with foremost domestic system integrators, including Daily Blockchain and STX Engine, to complete the VTS project. In addition, the project team will include worldwide surveillance solution providers, including SAAB, an eMARINE partner company, and Terma A/S. The Korean Coast Guard VTS project is budgeted at $14 million over two years.

With the negotiated terms of the contract, the project consortium will construct two VTS operating centers, one in Mokpo and one in Gunsan, both located on the southwest coast of Korea. The project will include three radar systems in Mokpo and two radar systems in Gunsan.

eMARINE Global, Inc. (EMRN), closed Thursday's trading session at $0.06, up 50.00%, on 170 volume with 4 trades. The average volume for the last 3 months is 732 and the stock's 52-week low/high is $0.0131/$3.00.

chart

MTB Corp. (BANM)

Zacks, Stock Twits, Morningstar, Barchart, Stockhouse, Equities.com, GuruFocus, InvestorsHub, Street Insider, Annual Reports, Dividend Investor, Seeking Alpha, YCharts, Investing.com, TradingView, and Simply Wall St reported earlier on MTB Corp. (BANM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

MTB Corp. is a fully integrated U.S. energy services company. It provides transportation, equipment rental, and other services to oil and gas producers. The Company has operations in Texas, Louisiana, Oklahoma and Pennsylvania. MTB Corp. lists on the OTC Markets. The Company is based in Frisco, Texas.

MTB does business as Banner Energy Services Corp. Banner Energy Services provides a broad variety of leading-edge production solutions and services. Banner offers transportation of frac sand and logistics services to hydraulic fracturing and drilling operators. In addition, it obtains and finances equipment to oilfield transportation services contractors.

Mr. Jay Puchir is President and Principal Financial Officer of Banner Energy Services. He is responsible for the Company’s executive leadership, mergers & acquisitions (M&As), capital allocation, performance management, as well as financial reporting. Most recently, Mr. Puchir served as the Chief Executive Officer and Chief Financial Officer of Ecoark Holdings (OTCQX: ZEST).

Mr. JD Reedy is the Chief Operating Officer of Banner Energy Services. Mr. Reedy oversees day-to-day operations, programs, and services. He is accountable for developing and executing sales and service plans to boost market growth for Banner. Mr. Reedy has a wide-ranging background in business development, field operations, and expanding market share within oil & gas service industries.

This past November, Banner Energy Services announced that it closed its earlier announced Merger with a subsidiary of Mount Tam Biotechnologies, Inc., effective November 18, 2019. Banner is the surviving entity and it becomes a subsidiary of Mount Tam.

Mount Tam received approval from its Board of Directors and shareholders and from FINRA for a name change to MTB Corp. and a reverse split of its common stock at a ratio of one new share for each 95 existing shares. On November 14, 2019, the reverse split and name change to MTB Corp. took effect. Moreover, the Company will take action to change the name from MTB Corp. to Banner Energy Services Corp.

MTB Corp. (BANM), closed Thursday's trading session at $1.40, up 39.986%, on 100 volume with 1 trade. The average volume for the last 3 months is 651 and the stock's 52-week low/high is $0.200000002/$7.59049987.

chart

Acro Biomedical Co., Ltd. (ACBM)

Connecting Investor, Penny Stock Hub, Stockwatch, Stock Digest, Simply Wall St, Market Screener, MarketWatch, GuruFocus, Barchart, GlobeNewswire, Wallmine, Bitcoin & Stock Journal, Last10k, YCharts, Morningstar, InvestorsHub, Trading View, Stockhouse, The Street, Credit Risk Monitor, Stockopedia, Wallet Investor, Dividend Investor, Seeking Alpha and Nasdaq reported on Acro Biomedical Co., Ltd. (ACBM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Acro Biomedical Co., Ltd. focuses on developing and marketing products that promote wellness and a healthy lifestyle. Its intention is to conduct research and development (R&D) on its own proprietary products based on cordyceps sinensis. The Company previously went by the name Killer Waves Hawaii, Inc. It changed its name to Acro Biomedical Co., Ltd. in January of 2017. Acro Biomedical is based in Fishers, Indiana.

Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. Cordyceps sinensis is a rare combination of a caterpillar and a fungus. It is found at altitudes above 4500m in Sikkim. Acro Biomedical originated from a group of scholars at the University of Taiwan. The Founder, Mr. Richard Chu, was looking for the materials for disease treatment and health care from traditional Chinese medicine and natural herbal medicine. The preferred material is China treasure, "Cordyceps".

The Company will operate in two main areas. These are health food development and new drug development. The first decade of Acro Biomedical was the development of scientific research to establish a combination of basic science. Since the founding of the Company, the target has always been scientific applications and market development.

The objective of establishing a technology and market integration business model centers on diverse areas. These include China, Southeast Asia, Northeast Asian, Central Asian and the Europe and United States market. Moreover, there are two special markets, one for the Chinese health industry market and one for the longevity of health care market.

In late December 2018, Acro Biomedical reported financial results for the year ended September 30, 2018. The Company generated revenue of $8.0 million and realized record Gross Profit in fiscal year 2018 of $0.83 million. Acro also generated positive Net Income of $0.42 million.

Revenue for the year ended September 30, 2018 was the above-mentioned $8.0 million, which represents an increase of $7.5 million versus $510,000 for the year ended September 30, 2017. Acro Biomedical did not generate any Revenue before Q4 of the year ended September 30, 2017.

Acro Biomedical Co., Ltd. (ACBM), closed Thursday's trading session at $2.50, up 42.8571%, on 100 volume with 1 trade. The average volume for the last 3 months is 214 and the stock's 52-week low/high is $1.75/$6.00.

chart

GulfSlope Energy, Inc. (GSPE)

TipRanks, Infront Analytics, Stockhouse, OTC Markets, Simply Wall St, Barchart, InvestorsHub, Emerging Growth, Zacks, Seeking Alpha, 4-Traders, GuruFocus, MarketWatch, Morningstar, Equity Clock, and Financial Times reported earlier on GulfSlope Energy, Inc. (GSPE), and we also highlight the Company, here at the QualityStocks Daily Newsletter.  

GulfSlope Energy, Inc. is an independent oil and natural gas company focusing on exploring offshore U.S. Gulf of Mexico. The Company uses 2.2 million acres of 3D seismic data to identify high quality exploration prospects. Its team has a track record of discovering and developing multi-billion-dollar projects internationally, with greater than 300 years of combined experience in the oil and gas exploration industry. OTCQB-listed, GulfSlope Energy is based in Houston, Texas.   

  GulfSlope’s target is the Shelf Miocene (2.2 MM Acres - 440 Blocks). Its current concentration is on pre-drill operations. The Company has a hybrid operating model with a preference to operate. The Miocene Subsalt Play – La Shelf has large resource potential; is low to moderate risk; has moderate drilling and development costs; has shortened times to initial production, and enhanced economics.

Regarding its Phase 1 Drilling Program, GulfSlope Energy has high-graded five prospects with mean unrisked resource potential of 623 MMboe. It is looking to capitalize on strategic advantages provided by exploration work to identify undervalued producing assets. GulfSlope has over 2 billion boe of net conventional recoverable resources. It has 23 lease blocks with 19 drilling prospects ranging from 30-280 MMboe. The average size of the prospects is 120 MMboe.

  GulfSlope Energy and Texas South Energy, Inc. (TXSO) previously entered into a strategic partnership with Delek Group Ltd., a global independent oil and gas company based in Israel. The Companies and Delek have mutually agreed to pursue oil and natural gas opportunities in the Gulf of Mexico.

Yesterday, GulfSlope Energy announced that its “Tau Prospect” well drilled through roughly 7,000 feet of salt where high pressures and hydrocarbons near the base of salt were encountered and major mud losses occurred. The interval was treated with lost circulation materials and cement. At present, GulfSlope Energy is tripping for a different drilling assembly to clean out the existing wellbore and possibly run casing before drilling below salt.

The Tau Prospect targets manifold Miocene sand levels trapped against a well-defined, angled flank of the large salt structure. The correlative target subsalt Miocene sand levels are oil productive at the close by subsalt Mahogany Field, about five miles to the southwest. GulfSlope estimates that a projected 16,000 foot total vertical depth will test initial resource potential in excess of 100 million barrels of oil equivalent for the Tau Prospect.

GulfSlope Energy, Inc. (GSPE), closed Thursday's trading session at $0.016, up 37.931%, on 2,742,069 volume with 69 trades. The average volume for the last 3 months is 1,688,287 and the stock's 52-week low/high is $0.005859999/$0.047200001.

chart

Vitality Biopharma, Inc. (VBIO)

Penny Stock Tweets, Zacks, The OTC Reporter, Finance Registrar, MarketWatch, GuruFocus, Stock Beast, SmallCap Network, Stockhouse, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s dedication is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, the Company has developed a unique capability to produce molecules via glycosylation. This is a form of enzymatic biosynthesis, which was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products. OTCQB-listed, Vitality Biopharma has its headquarters in Los Angeles, California. 

  Late in 2015, Vitality successfully modified cannabidiol (CBD), which is not psychoactive. In continuing work, the Company has created a novel class of pharmaceuticals called cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Vitality Biopharma can biosynthesize cannabinoid glycosides (cannabosides) via enzyme biosynthesis. The Company is one of only a very few groups in the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides). 

  Vitality Biopharma has developed a proprietary biosynthesis technology that can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds called cannabinoid glycosides, or cannabosides.

The Company has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality is centering initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. The treatment indications it plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain).

Vitality Biopharma announced in April 2018 the pending establishment of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd. This subsidiary will focus on and enable the performance of a wide assortment of cannabinoid genetics research and development (R&D) programs. Vitality Biopharma announced in May the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis. In experiments executed according to guidance by the Clinical Laboratory and Standards Institute (CLSI), Vitality determined that cannabinoids (including THC) are effective antibiotics for C. diff, VRE, and a variety of additional pathogens.

Last month, Vitality Biopharma announced that during a recent in vitro safety pharmacological screening study, its lead drug candidate VBX-100 demonstrated no signs of adverse pharmacological effects. This affirms its potential for extensive clinical use as a GI-targeted prodrug of THC. Vitality Biopharma has filed for intellectual property (IP) protection on greater than 100 different glycoside prodrugs. This includes VBX-100.

Vitality Biopharma, Inc. (VBIO), closed Thursday's trading session at $0.0999, up 99.80%, on 100,037 volume with 15 trades. The average volume for the last 3 months is 25,126 and the stock's 52-week low/high is $0.0051/$0.349999994.

chart

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the worldwide pressure technologies industry, announced that SkinScience Labs, a pending accretive acquisition of the Company, has received an initial $3.5 million order for its premium FDA-registered dermatological hand sanitizer product (http://nnw.fm/3UXmq).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday's trading session at $2.378, up 0.337553%, on 10,279 volume with 28 trades. The average volume for the last 3 months is 16,523 and the stock's 52-week low/high is $0.600600004/$4.48999977.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (“PDx”) through its distributor US Biological Corporation. To view the full press release, visit http://nnw.fm/Vtrv5

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.99, up 15.6977%, on 3,710,331 volume with 10,460 trades. The average volume for the last 3 months is 864,376 and the stock's 52-week low/high is $1.25/$8.50.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) was featured today in the 420 with CNW by CannabisNewsWire. Canada has made great inroads into the nascent global cannabis industry. As public opinion slowly turns in favor of cannabis, a handful of countries, including Canada, have legalized either medical and adult-use cannabis or both. The Great White North is among the biggest exporters of medical marijuana oil in the world, and according to data from Health Canada, Canadian-produced medical marijuana oil reached more international shores than ever last year.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Thursday's trading session at $0.541, up 4.7435%, on 16,258 volume with 25 trades. The average volume for the last 3 months is 35,047 and the stock's 52-week low/high is $0.279000014/$4.03999996.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint’s (OTCQB: SING) Direct Solar America subsidiary is broadening its market reach and through a referral agreement, is partnering with a pioneer in solar financing, Dividend Financial. According to the update, the agreement significantly lowers cost of acquisition of new clients seeking to install or finance commercial solar projects that currently are not included in the offerings provided by Dividend Financial. To view the full press release, visit http://nnw.fm/nvo9U.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Thursday's trading session at $0.0053, up 6.00%, on 3,082,825 volume with 127 trades. The average volume for the last 3 months is 5,480,902 and the stock's 52-week low/high is $0.004/$0.021999999.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

More than 60% of Americans have personally experienced a major data breach, and roughly half do not trust social media sites to protect their personal information (http://nnw.fm/ZrZ0k). These findings by Pew Research Center don’t surprise the data security experts at SRAX (NASDAQ: SRAX), a digital marketing company focused on providing consumer data-management services and pioneering technology that allows consumers to control their own information — and be compensated when they choose to share that information.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $2.06, off by 5.9361%, on 47,907 volume with 146 trades. The average volume for the last 3 months is 54,679 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

chart

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (CSE: SHRM).

Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) was featured today in the 420 with PNW by CannabisNewsWire. A new Netflix documentary called “Have a Good Trip: Adventures in Psychedelics” premiered on Netflix on May 11 this year and it is generating quite a buzz because of the topic it explores. In this documentary, several stars share their experiences of taking psychedelic drugs. Actors reenact those experiences being described by the celebrities, and experts delve into the science of why and what psychedelics can offer the medical community.

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

  • Alternative medicine (psilocybin) IP aggregation
  • Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
  • Drafting of benchmark SOPs (Standard Operating Procedures)
  • Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

  • Non-Hallucinogenic Medicines
    • Microdosing Psilocybin/LSD
    • MDMA, commonly known as ecstasy
  • Hallucinogenic Medicines
    • Psilocybin high dose
    • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (CSE: SHRMF), closed Thursday's trading session at $0.62, off by 7.0883%, on 529,330 volume with 482 trades. The average volume for the last 3 months is 623,645 and the stock's 52-week low/high is $0.221/$1.74.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company") announces that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with securities regulatory authorities in each province of Canada.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Thursday's trading session at $0.16, off by 4.1916%, on 538,808 volume with 69 trades. The average volume for the last 3 months is 130,784 and the stock's 52-week low/high is $0.109999999/$0.514999985.

Recent News

chart

The Movie Studio Inc. (OTC: MVES)

The QualityStocks Daily Newsletter would like to spotlight The Movie Studio Inc. (OTC: MVES).

The Movie Studio (OTC: MVES), a vertically integrated motion picture production company engaged in the acquisition, development, production and distribution of independent motion picture content for worldwide consumption, today announced that its founder, president & CEO, Gordon Scott Venters, has been featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company and one of 45+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Venters provided details on The Movie Studio’s strategy to disrupt the video on demand (“VOD”) industry as major players like Disney and Viacom continue to announce massive acquisitions in the space. To view the full press release, visit http://nnw.fm/bz55F

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

  • Purchasing legacy film libraries.
  • Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
  • Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
  • Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
  • Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

The Movie Studio Inc. (OTC: MVES), closed Thursday's trading session at $0.0071, off by 19.3182%, on 1,053,891 volume with 35 trades. The average volume for the last 3 months is 128,036 and the stock's 52-week low/high is $0.006099999/$0.07.

Recent News

chart

Wrap Technologies Inc. (NASDAQ: WRTC)

The QualityStocks Daily Newsletter would like to spotlight Wrap Technologies Inc. (NASDAQ: WRTC).

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced its receipt of new international purchase orders from three countries in Asia for over 200 BolaWrap devices, more than 2,600 cartridges and accessories. Two of the orders are follow-ons from demonstrations and trainings conducted last year, while the third is an initial order from a new country beginning BolaWrap demonstrations and trials this year. To view the full press release, visit http://nnw.fm/riQ4z

Wrap Technologies Inc. (NASDAQ: WRTC) is an innovator of modern policing solutions. The company’s BolaWrap® product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (http://nnw.fm/ri0L9). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (http://nnw.fm/YVm8P). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (http://nnw.fm/2Nb1A).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

  • “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
  • “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.” – Redditt Hudson, Regional Field Director of the NAACP (http://nnw.fm/1STXm)
  • “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
  • “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be use to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (http://nnw.fm/byLV7). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap® technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which, through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation), and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

Wrap Technologies Inc. (NASDAQ: WRTC), closed Thursday's trading session at $9.69, up 15.0831%, on 3,174,254 volume with 15,830 trades. The average volume for the last 3 months is 821,471 and the stock's 52-week low/high is $3.06999993/$10.00.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Thursday's trading session at $1.48, off by 1.3333%, on 191,628 volume with 925 trades. The average volume for the last 3 months is 930,548 and the stock's 52-week low/high is $0.610000014/$6.42999982.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement." To view the full press release, visit http://cnw.fm/KGZ3n

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.29, off by 0.51458%, on 6,336 volume with 23 trades. The average volume for the last 3 months is 114,159 and the stock's 52-week low/high is $0.217899993/$1.00.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) today announced receipt of its first major purchase order out of Australia for its UV350 dedicated in-vehicle IoT device, valued at approximately $300,000. To view the full press release, visit http://nnw.fm/ztK46.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Thursday's trading session at $0.0861, off by 4.3333%, on 45,715 volume with 7 trades. The average volume for the last 3 months is 162,495 and the stock's 52-week low/high is $0.0722/$0.392500013.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Thursday's trading session at $6.29, up 2.443%, on 8,690 volume with 158 trades. The average volume for the last 3 months is 124,776 and the stock's 52-week low/high is $3.23399996/$11.6000003.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Thursday's trading session at $0.003, up 7.1429%, on 48,746,423 volume with 726 trades. The average volume for the last 3 months is 34,403,284 and the stock's 52-week low/high is $0.001599999/$0.038899999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.